TABLE 2

Published and Presented Studies with PET-Adapted Therapy in NHL

StudyDesignPatient populationnPET after“Positive” equivalent toPET-negative therapyPET-positive therapyMedian follow-upOutcome
Duehrsen PETAL 2014 (17)RCTAggressive NHL (80% DLBCL)8532×R-CHOP<66% ∆SUV reduction4×R-CHOP or 4×R-CHOP+2R6×R-CHOP or 6×Burkitt protocol33 mo2-y TTF: PET-neg 79%; PET-pos 47%; 2R, no difference (HR 1.2, 95% CI 0.8–2.1)
Intensification: no difference (HR 1.6, 95% CI 0.9–2.7)
Sehn BCCA 2014 (18)Ph IIAdvanced-stage DLBCL/PMBCL1554×R-CHOPDS 3–52×R-CHOP4×R-ICE+RT if EOT PET-pos45 mo4-y PFS: PET-neg 91%; PET-pos 59%
4-y OS: PET-neg 96%; PET-pos 73%
Hertzberg ALLG 2017 (19)Ph IIPoor-risk DLBCL1514×R-CHOPDS 3–52×R-CHOP+2R3×R-ICE+Z-BEAM ASCT35 mo2-y PFS: PET-neg 74%; PET-pos 67%
2-y OS: PET-neg 78%; PET-pos 88% (P = 0.11)
  • PETAL = PET-guided therapy of aggressive lymphomas; DLBCL = diffuse large B-cell lymphoma; (R-)CHOP = (rituximab) cyclophosphamide, doxorubicin, vincristine, and prednisone; 2R = 2 cycles rituximab; TTF = time to treatment failure; BCCA = British Columbia Cancer Agency; (R-)ICE = (rituximab) ifosfamide, carboplatin, etoposide; EOT = end of treatment; ALLG = Australasian Leukaemia Lymphoma Study Group; Z-BEAM = ibritumomab tiuxetan, carmustine, etoposide, cytarabine, and melphalan; ASCT = autologous stem cell transplantation; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.